iBio (IBIO) Competitors $2.48 +0.06 (+2.48%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends IBIO vs. QNCX, TNXP, PMVP, ALXO, IKNA, CLSD, ENTX, GNLX, IMAB, and PYRGFShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Quince Therapeutics (QNCX), Tonix Pharmaceuticals (TNXP), PMV Pharmaceuticals (PMVP), ALX Oncology (ALXO), Ikena Oncology (IKNA), Clearside Biomedical (CLSD), Entera Bio (ENTX), Genelux (GNLX), I-Mab (IMAB), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. iBio vs. Quince Therapeutics Tonix Pharmaceuticals PMV Pharmaceuticals ALX Oncology Ikena Oncology Clearside Biomedical Entera Bio Genelux I-Mab PyroGenesis Canada Quince Therapeutics (NASDAQ:QNCX) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Does the media refer more to QNCX or IBIO? In the previous week, Quince Therapeutics had 8 more articles in the media than iBio. MarketBeat recorded 10 mentions for Quince Therapeutics and 2 mentions for iBio. Quince Therapeutics' average media sentiment score of 0.79 beat iBio's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is QNCX or IBIO more profitable? Quince Therapeutics' return on equity of -53.27% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% iBio N/A -78.53%-41.79% Which has preferable valuation & earnings, QNCX or IBIO? iBio has higher revenue and earnings than Quince Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.44iBio$175K129.65-$24.91MN/AN/A Do insiders & institutionals believe in QNCX or IBIO? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer QNCX or IBIO? Quince Therapeutics received 2 more outperform votes than iBio when rated by MarketBeat users. Likewise, 100.00% of users gave Quince Therapeutics an outperform vote while only 42.86% of users gave iBio an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes5100.00% Underperform VotesNo VotesiBioOutperform Votes342.86% Underperform Votes457.14% Do analysts prefer QNCX or IBIO? Quince Therapeutics currently has a consensus price target of $8.67, indicating a potential upside of 386.89%. iBio has a consensus price target of $4.30, indicating a potential upside of 73.39%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, QNCX or IBIO? Quince Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, iBio has a beta of -3.24, suggesting that its stock price is 424% less volatile than the S&P 500. SummaryQuince Therapeutics beats iBio on 13 of the 15 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$22.69M$6.57B$5.12B$19.18BDividend YieldN/A2.98%4.91%3.59%P/E RatioN/A10.5991.3441.28Price / Sales129.65195.381,116.5917.59Price / CashN/A57.1642.6421.28Price / Book1.005.104.795.32Net Income-$24.91M$151.51M$120.07M$989.88M7 Day Performance7.36%-2.15%-1.89%-3.54%1 Month Performance1.22%-3.14%11.45%-3.68%1 Year PerformanceN/A11.50%30.61%12.14% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio0.995 of 5 stars$2.48+2.5%$4.30+73.4%N/A$22.69M$175,000.000.00100QNCXQuince Therapeutics3.0834 of 5 stars$1.92-5.4%$8.50+342.7%+60.4%$84.48MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoverageTNXPTonix Pharmaceuticals3.6123 of 5 stars$0.44+83.8%$53.50+12,001.3%-95.0%$82.63M$11.29M0.00103High Trading VolumePMVPPMV Pharmaceuticals1.7962 of 5 stars$1.58flat$5.80+267.1%-34.5%$81.77MN/A0.0050Positive NewsALXOALX Oncology3.191 of 5 stars$1.54+6.2%$10.67+592.6%-87.7%$81.22MN/A-0.4940Analyst ForecastNews CoverageIKNAIkena Oncology2.8796 of 5 stars$1.65flat$3.00+81.8%-20.5%$79.63M$659,000.00-1.3470CLSDClearside Biomedical2.9023 of 5 stars$1.04+2.1%$5.33+412.3%-12.8%$78.95M$8.23M-2.2930News CoverageENTXEntera Bio1.4405 of 5 stars$2.20+1.9%$10.00+354.5%+195.8%$78.72M$130,000.00-8.3120GNLXGenelux0.8851 of 5 stars$2.27-2.6%$18.25+704.0%-82.9%$78.40M$8,000.00-2.4510IMABI-Mab2.3516 of 5 stars$0.96-4.2%$8.00+734.8%-38.9%$78.10M$3.27M0.0034Gap DownPYRGFPyroGenesis CanadaN/A$0.42+3.2%N/A+15.9%$77.96M$9.14M-6.8490 Related Companies and Tools Related Companies QNCX Alternatives TNXP Alternatives PMVP Alternatives ALXO Alternatives IKNA Alternatives CLSD Alternatives ENTX Alternatives GNLX Alternatives IMAB Alternatives PYRGF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IBIO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
